What is VolitionRx?
VolitionRx is a pioneering life sciences enterprise dedicated to the advancement of diagnostic testing for cancer and various other medical conditions. At the core of its operations is the science of Nucleosomics, a sophisticated methodology that identifies and quantifies nucleosomes within bodily fluids to detect the presence of disease. By transforming complex biological markers into actionable clinical data, the company aims to standardize diagnostic testing, making it as accessible and routine as common cholesterol or diabetic screenings.
Currently, the firm maintains a robust research and development footprint in Belgium. This strategic location serves as the primary hub for its efforts to introduce diagnostic products to the European market, with subsequent expansion plans targeting the United States and global healthcare systems. The company's focus remains on bridging the gap between laboratory innovation and bedside utility.
How much funding has VolitionRx raised?
VolitionRx has raised a total of $5.7M across 3 funding rounds:
Debt
$1.2M
Debt
$500K
Other Financing Round
$4M
Debt (2017): $1.2M with participation from SOFINEX
Debt (2019): $500K led by Texas A&M SOFINEX
Other Financing Round (2021): $4M supported by Namur Invest
Key Investors in VolitionRx
Namur Invest
Namur Invest is a public-private partnership providing tailored financing solutions to businesses in the Namur province, focusing on innovation and long-term growth.
SOFINEX
SOFINEX is a specialized investment entity focused on supporting the international development and financial structuring of growing enterprises.
Texas A&M SOFINEX
An institutional participant in the funding round, contributing to the capital requirements for advanced medical research and development.
What's next for VolitionRx?
With the recent influx of capital, VolitionRx is well-positioned to transition from its research-heavy phase into a broader commercialization strategy. The company is expected to prioritize the regulatory approval processes necessary for market entry in the U.S., while simultaneously scaling its manufacturing and distribution capabilities in Europe. As the firm continues to refine its Nucleosomics platform, the focus will likely shift toward securing strategic partnerships with major healthcare providers to integrate its diagnostic tests into standard clinical workflows. This phase of growth is critical for establishing VolitionRx as a leader in non-invasive cancer detection, ultimately aiming to improve patient outcomes through early and accurate diagnosis.
See full VolitionRx company page
